Literature DB >> 25087999

Serum vitamin D is associated with non-alcoholic fatty liver disease in Chinese males with normal weight and liver enzymes.

Ya-ping Hao1, Xiao-jing Ma1, Yu-qi Luo1, Jie Ni1, Jian-xin Dou1, Ya-qin Hu1, Jia-an Zhu2, Yu-qian Bao1, Wei-ping Jia1.   

Abstract

AIM: Considering the characterization of vitamin D deficiency as a risk factor of ectopic fat deposition, the association of serum 25-hydroxy vitamin D3 [25(OH)D3] levels with non-alcoholic fatty liver disease (NAFLD) was evaluated in Chinese men with normal body mass index (BMI) and enzyme markers of liver function.
METHODS: A total of 514 participants (22 to 79 years old) with normal BMI and liver enzymes were identified for analysis. Abdominal ultrasound was performed to diagnose NAFLD, and the fatty liver index (FLI) was calculated to quantify liver steatosis. Serum 25(OH)D3 levels were determined by an electrochemiluminescence immunoassay.
RESULTS: Among the entire study population, the mean levels of serum 25(OH)D3 were 15.32±5.77 ng/mL. However, when serum 25(OH)D3 levels were compared between non-NAFLD subjects (n=438) and NAFLD subjects (n=76), the latter showed significantly lower levels (15.65±5.89 ng/mL vs 13.46±4.65 ng/mL, P=0.002). In addition, serum 25(OH)D3 levels were found to be significantly correlated with FLI after adjustment for age and BMI (r=-0.108, P=0.014). Logistic regression showed that serum 25(OH)D3 levels were independently correlated with NAFLD (OR: 0.937, 95% CI: 0.884-0.993, P=0.028). Furthermore, stepwise regression analysis revealed that serum 25(OH)D3 levels were inversely associated with FLI (β=-0.055, P=0.040).
CONCLUSION: The present study demonstrated that serum 25(OH)D3 levels were inversely associated with NAFLD, even in subjects with normal total body fat, suggesting a potential role of lower levels of vitamin D in the occurrence and development of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25087999      PMCID: PMC4155526          DOI: 10.1038/aps.2014.48

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  30 in total

1.  Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition.

Authors:  Fan Jian-gao
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2010-03

2.  Determination of vitamin D in relation to body mass index and race in a defined population of black and white women.

Authors:  Ponjola Coney; Laurence M Demers; William C Dodson; Allen R Kunselman; Gwinnett Ladson; Richard S Legro
Journal:  Int J Gynaecol Obstet       Date:  2012-07-18       Impact factor: 3.561

3.  Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency.

Authors:  Sigrid Hatse; Diether Lambrechts; Annemieke Verstuyf; Ann Smeets; Barbara Brouwers; Thijs Vandorpe; Olivier Brouckaert; Gilian Peuteman; Annouschka Laenen; Lieve Verlinden; Carsten Kriebitzsch; Anne-Sophie Dieudonné; Robert Paridaens; Patrick Neven; Marie-Rose Christiaens; Roger Bouillon; Hans Wildiers
Journal:  Carcinogenesis       Date:  2012-05-23       Impact factor: 4.944

4.  Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes.

Authors:  Sakineh Shab-Bidar; Tirang R Neyestani; Abolghassem Djazayery; Mohammad-Reza Eshraghian; Anahita Houshiarrad; Ali Kalayi; Nastaran Shariatzadeh; Niloufar Khalaji; A'azam Gharavi
Journal:  Diabetes Metab Res Rev       Date:  2012-02-17       Impact factor: 4.876

5.  Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease.

Authors:  K L Jablonski; A Jovanovich; J Holmen; G Targher; K McFann; J Kendrick; M Chonchol
Journal:  Nutr Metab Cardiovasc Dis       Date:  2013-02-13       Impact factor: 4.222

6.  Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease.

Authors:  Giovanni Targher; Lorenzo Bertolini; Luca Scala; Massimo Cigolini; Luciano Zenari; Giancarlo Falezza; Guido Arcaro
Journal:  Nutr Metab Cardiovasc Dis       Date:  2006-08-22       Impact factor: 4.222

7.  Association of serum 25-hydroxyvitamin D with insulin resistance and β-cell function in a healthy Chinese female population.

Authors:  Min-fang Tao; Zeng Zhang; Yao-hua Ke; Jin-wei He; Wen-zhen Fu; Chang-qing Zhang; Zhen-lin Zhang
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

8.  Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells.

Authors:  Jorge N Artaza; Keith C Norris
Journal:  J Endocrinol       Date:  2008-11-26       Impact factor: 4.286

Review 9.  Metabolic and body composition factors in subgroups of obesity: what do we know?

Authors:  Antony D Karelis; David H St-Pierre; Florence Conus; Remi Rabasa-Lhoret; Eric T Poehlman
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

10.  Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.

Authors:  Deepa Uchil; D Pipalia; M Chawla; R Patel; Sonali Maniar; Archana Juneja
Journal:  J Assoc Physicians India       Date:  2009-03
View more
  10 in total

1.  Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.

Authors:  Xiang Wang; Weiping Li; Ying Zhang; Yang Yang; Guijun Qin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort.

Authors:  Samar R El Khoudary; Saad Samargandy; Irfan Zeb; Temitope Foster; Ian H de Boer; Dong Li; Matthew J Budoff
Journal:  Nutr Metab Cardiovasc Dis       Date:  2019-09-10       Impact factor: 4.222

Review 3.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

4.  Association and interaction between vitamin D level and metabolic syndrome for non-alcoholic fatty liver disease.

Authors:  Salam Bennouar; Abdelghani Bachir Cherif; Amel Kessira; Djamel Eddine Bennouar; Samia Abdi
Journal:  J Diabetes Metab Disord       Date:  2021-07-21

5.  Inverse relationship between serum osteocalcin levels and nonalcoholic fatty liver disease in postmenopausal Chinese women with normal blood glucose levels.

Authors:  Yu-qi Luo; Xiao-jing Ma; Ya-ping Hao; Xiao-ping Pan; Yi-ting Xu; Qin Xiong; Yu-qian Bao; Wei-ping Jia
Journal:  Acta Pharmacol Sin       Date:  2015-11-16       Impact factor: 6.150

6.  Neck circumference as an independent indicator to non-alcoholic fatty liver disease in non-obese men.

Authors:  Qin Li; Ningjian Wang; Bing Han; Yi Chen; Chunfang Zhu; Yingchao Chen; Fangzhen Xia; Zhen Cang; Chaoxia Zhu; Chi Chen; Hualing Zhai; Boren Jiang; Dongping Lin; Yingli Lu
Journal:  Nutr Metab (Lond)       Date:  2015-12-30       Impact factor: 4.169

Review 7.  Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?

Authors:  Ying Cao; Xiang-Bing Shu; Zemin Yao; Guang Ji; Li Zhang
Journal:  World J Gastroenterol       Date:  2020-10-14       Impact factor: 5.742

8.  Low serum vitamin D concentrations are associated with obese but not lean NAFLD: a cross-sectional study.

Authors:  Qinqiu Wang; Xiaoying Shi; Jinghua Wang; Juanwen Zhang; Chengfu Xu
Journal:  Nutr J       Date:  2021-04-01       Impact factor: 3.271

Review 9.  Can skin exposure to sunlight prevent liver inflammation?

Authors:  Shelley Gorman; Lucinda J Black; Martin Feelisch; Prue H Hart; Richard Weller
Journal:  Nutrients       Date:  2015-05-05       Impact factor: 5.717

10.  Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults.

Authors:  Toshihiro Umehara
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.